Aging: Gene silencing or gene activation?

Medical Hypotheses

Volumn 64, Issue 1, 2005, Pages 201-208

  Burzynski, Stanislaw R ^a  

^a Burzynski Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLACETAMIDO 2,6 PIPERIDINEDIONE; AMINO ACID; AMINOCARE; AMINOCARE EXTRA; CARCINOGEN; GENISTEIN; HISTONE; LIMONENE; METHYLTRANSFERASE; PHENYLACETIC ACID; PHENYLACETYLGLUTAMINE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; RESVERATROL; SOMATOMEDIN; UNCLASSIFIED DRUG;

AGING; APOPTOSIS; CALORIC RESTRICTION; CANCER PREVENTION; CELL CYCLE; CHOLESTEROL METABOLISM; CHROMATIN; DEACETYLATION; DETOXIFICATION; DIET SUPPLEMENTATION; DNA METHYLATION; DRUG DNA INTERACTION; DRUG MECHANISM; FLY; GENE ACTIVATION; GENE ACTIVITY; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENE THERAPY; GENETIC STABILITY; GENOMICS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; WORM; YEAST;

ANIMALIA;

EID: 7944239285     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.06.010     Document Type: Article

References (56)

1. S.R. Burzynski Gene silencing - a new theory of aging Med. Hypotheses 60 2003 578 583
2. A.P. Feinberg, and B. Tycko The history of cancer epigenetics Nat. Rev. Can. 4 2004 143 153
3. P.A. Jones, and D. Takai The role of DNA methylation in mammalian epigenetics Science 293 2001 1068 1070
4. J.M. Ordway, and T. Curran Methylation matters: modeling a manageable genome Cell Growth Differ. 13 2002 149 162
5. E. Li Chromatin modification and epigenetic reprogramming in mammalian development Nat. Rev. Gen. 3 2002 662 673
6. E. Fibach, P. Prasanna, G.P. Rodger, and D. Samid Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and thalassemia Blood 82 1993 2203 2209
7. M. Esteller, P.G. Com, S.B. Baylin, and J.G. Herman A gene hypermethylation profile of human cancer Cancer Res. 61 2001 3225 3229
8. M. Widschwender, and P.A. Jones The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer Clin. Cancer Res. 8 2002 17 21
9. A. Lafuente, F. Pujol, and P. Caretero Human glutathione S-transferase mu (GSTμ) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers Cancer Lett. 68 1993 49 54
10. J. Campisi Cancer and ageing: rival demons? Nat. Rev. Can. 3 2003 339 349
11. C.W.M. Roberts, and S.H. Orkin The SWI/SNF complex - chromatin and cancer Nat. Rev. Can. 4 2004 133 142
12. P.W. Laird The power and the promise of DNA methylation markers Nat. Rev. Can. 3 2003 253 266
13. F. Gaudet, J. Graeme Hodgson, and A. Eden Induction of tumors in mice by genomic hypomethylation Science 300 2003 489 492
14. A. Eden, F. Gaudet, A. Waghmare, and R. Jaenisch Chromosomal instability and tumors promoted by DNA hypomethylation Science 300 2003 455
15. O.M. Sieber, K. Heinimann, and I.P.M. Tomlinson Genomic instability - the engine of tumorigenesis? Nat. Rev. Can. 3 2003 701 708
16. V. Schramke, and R. Allshire Hairpin RNAs and retrotransposon LTRs effect RNAi and chromatin-based gene silencing Science 301 2003 1069 1074
17. C. Kenyon A conserved regulatory system for aging Cell 105 2001 165 168
18. C.T. Murphy, S.A. McCarroll, and C.I. Bargmann Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans Nature 424 2003 277 284
19. S.X. Cao, J.M. Dhahbi, P.L. Mote, and S.R. Spindler Genomic profiling of short- and long-term caloric restriction effects in the liver of aging mice PNAS 98 2001 10630 10635
20. B.D. Longo, and C.E. Finch Evolutionary medicine: from dwarf model systems to healthy centenarians? Science 299 2003 1342 1346
21. M.F. White Insulin signaling in health and disease Science 302 2003 1710 1711
22. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-kinase-AKT pathway in human cancer Nat. Rev. Can. 2 2002 489 501
23. M. Malumbres, and M. Barbacid RAS oncogens: the first 30 years Nat. Rev. Can. 3 2003 459 465
24. K.T. Howitz, K.J. Bitterman, and H.Y. Cohen Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan Nature 424 2003 1 5
25. A. Brunet, L.B. Sweeney, and J. Sturgill Fitzhugh Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase Science 303 2004 2011 2015
26. J. Campisi Fragile fugue: p53 in aging, cancer and IFG signaling Nat. Med. 10 2004 231 232
27. K.H. Vousden, and X. Lu Live or let die: the cell's response to p53 Nat. Rev. Can. 2 2002 594 604
28. G. Melino, V. De Laurenzi, and K.H. Vousden p73: friend or foe in tumorigenesis Nat. Rev. Can. 2 2002 605 615
29. R. Bernards Wip-ing out cancer Nat. Genetics 16 2004 319 320
30. Arfpathway Nat. Gen. 36 2004 343 350
31. B. Maier, W. Gluba, and B. Bernier Modulation of mammalian life span by the short isoform of p53 Genes Dev. 18 2003 306 319
32. A.W. Lin, M. Barradas, J.C. Stone, L. van Aelst, M. Serrano, and S.W. Lowe Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling Genes Dev. 12 1998 3008 3019
33. S.D. Tyner, S. Venkatachalam, and J. Choi p53 mutant mice that display early ageing-associated phenotypes Nature 415 2002 45 53
34. J.D. Vigne, J. Guilaine, K. Debue, L. Haye, and P. Gérard Early taming of the cat in Cyprus Science 304 2004 259
35. Z. Laron The essential role of IGF-1: lessons from the long-term study and treatment of children and adults with Laron syndrome J. Clin. Endocrinol. Metab. 84 1999 4397 4404
36. Y.J. Surh Cancer chemoprevention with dietary phytochemicals Nat. Rev. Can. 3 2003 768 780
37. L. Gong, Y. Li, A. Nedeljovic-Kurepa, and F.H. Sakar Inactivation of NF-κB by genistein is mediated via Akt signaling pathway in breast cancer cells Oncogene 22 2003 4702 4709
38. Y. Li, and F.H. Sarjar Inhibition of nuclear factor κB activation in PC3 cells by genistein is mediated via Akt signaling pathway Clin. Cancer Res. 22 2002 4702 4709
39. S.M. Plummer Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signaling complex Oncogene 18 1999 6013 6020
40. V. Granados-Soto Pleiotropic effects of resveratrol Drug News Perspect 16 2003 299 307
41. S.R. Burzynski The present state of antineoplaston research (1) Integrative Can. Ther. 3 2004 47 58
42. S.R. Burzynski, L.B. Hendry, and M.O. Mohabbat Purification, structure determination, synthesis and animal toxicity studies of Antineoplaston A10 Proc. 13th Int Cong. Chemother. 17 1983 PS.12.4.11 PS.12.4.14
43. S.R. Burzynski, M.O. Mohabbat, and B. Burzynski Human toxicology studies on oral formulation of Antineoplaston A10 Drugs Exp. Clin. Res. 10 1984 891 909
44. B.N. Kampalath, M.C. Liau, B. Burzynski, and S.R. Burzynski Chemoprevention by antineoplaston A10 of benzo[a]pyrene-induced pulmonary neoplasia Drugs Exp. Clin. Res. 13 1 Suppl. 1987 51 55
45. B.N. Kampalath, M.C. Liau, B. Burzynski, and S.R. Burzynski Protective effect of antineoplaston A10 in hepatocarcinogenesis induced by aflatoxin B1 Int. J. Tissue React. 12 1 Suppl. 1990 43 50
46. T.G. Muldoon, J.A. Copland, and L.B. Hendry Actions of Antineoplaston A10 on the genesis and maintenance of specific subpopulation of rodent mammary tumor cells Adv. Exp. Clin. Chemother 2 1988 15 18
47. L.B. Hendry, and T.G. Muldoon Actions of an endogenous antitumorigenic agent on mammary tumor development and modeling analysis of its capacity for interacting with DNA J. Steroid Biochem. 30 1988 325 328
48. N. Eriguchi, H. Hara, H. Yoshida, H. Nishida, T. Nakayama, and K. Ohishi Chemopreventive effect of antineoplaston A10 on urethane-induced pulmonary neoplasm in mice J. Jpn. Soc. Cancer Ther. 23 1988 1560 1565
49. A.Q. Ashraf, M.C. Liau, M.O. Mohabbat, and S.R. Burzynski Preclinical studies of Antineoplaston A10 injections Drugs Exp. Clin. Res. 12 1 suppl 1986 37 45
50. S.R. Burzynski, M.O. Mohabbat, and S.S. Lee Preclinical studies of Antineoplaston AS2-1 and Antineoplaston AS2-5 Drugs Exp. Clin. Res. 12 1 Suppl 1986 11 16
51. R. Waldbillig, and S.R. Burzynski Mechanism of action, uptake, and gene array studies on the antineoplastic agent phenylacetylglutamine (PG) in human glioma cells U-87 Neuro-Oncology 5 2003 309
52. S. Shack, L.C. Chen, A.C. Miller, R. Danesi, and D. Samid Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21 ras isoprenylation and phenotypic reversion Int. J. Cancer 63 1995 124 129
53. M. Gorospe, S. Shack, K.Z. Guyton, D. Samid, and N.J. Holbrook Up-regulation and functional role of p21 Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate Cell Growth Differ. 7 1996 1609 1615
54. S.R. Burzynski, E. Kubove, and B. Burzynski Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1 Drugs Exp. Clin. Res. 16 1990 361 369
55. A.F. Collins, H.A. Pearson, P. Giardina, K.T. McDonagh, S.W. Brusilow, and G.J. Dover Oral sodium phenylbutyrate therapy in homozygous beta-thalassemia: a clinical trial Blood 85 1995 43 49
56. WAF1/Cip1and gelsolin are induced Neuro-Oncology 4 2002 95 101